Follow Us:

Chugai Pharma Opens $200m Antibody Lab In Singapore

Tokyo-based Chugai Pharmaceutical Co., Ltd. has officially opened a new laboratory in Singapore that will conduct research into new antibody drugs.

| July 16, 2012 | Pharma

AsianScientist (Jul. 16, 2012) – Tokyo-based Chugai Pharmaceutical Co., Ltd. officially opened on Friday a new laboratory in Singapore that will conduct research into new antibody drugs.

The Singapore-based Chugai Pharmabody Research Pte. Ltd. (CPR) will screen antibody drug candidates for therapeutic potential using Chugai’s proprietary antibody engineering technologies.

The new facility will be located at Singapore’s Biopolis R&D hub and employ approximately 60 researchers. A*STAR Chief Scientist David Lane is the chairman of the board of the venture.

Chugai is expected to invest S$200 million (US$158 million) into the lab over five years.

According to a company press statement, CPR aims to generate five or more drug candidates per year for its drug pipeline. It will make use of its proprietary recycling antibody technology, which uses a single antibody molecule to repeatedly block the function of the target antigen and eliminate it from plasma.

CPR will be Chugai’s fourth satellite research institute following its C&C Research Laboratories in South Korea; Pharmalogicals Research Pte. Ltd. in Singapore; and Forerunner Pharma Research Co., Ltd. in Tokyo.
 
Chugai Pharma’s latest venture follows a number of Japanese companies that are setting up R&D hubs in Singapore.

In April 2012, Toshiba Corporation opened an Aqua Research Center at the WaterHub in Singapore, its first water treatment R&D center located outside of Japan.

In February 2012, petrochemical manufacturer Sumitomo Chemical opened a solution styrene-butadiene rubber (S-SBR) manufacturing plant in Singapore.

——

Source: Chugai Pharma.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

blog comments powered by Disqus

RELATED STORIES FROM ASIAN SCIENTIST

Subscribe to our newsletter

Subscribe to our newsletter